Team

Bernard Malfroy-Camine
Johannes Fruehauf
Lisa Velardo
F. Stephen Laroux
Laura Holberger

Directors and Advisors

Peter Parker
Philippe Langella
Pamela Avallone
R. Balfour Sartor
Dirk Brockstedt
Josh Korzenik
Catherine Grillot Courvalin
Thomas E. Spike

Team

Bernard Malfroy-Camine (PhD) (President and Chief Executive Officer)
Dr. Malfroy-Camine joined ViThera as a strategic consultant in 2011 and was appointed CEO in May 2013. He combines the unique experience of a French-American scientist-entrepreneur. Dr. Malfroy-Camine brings nearly 30 years of industry experience to ViThera, from Genentech, Alkermes, Eukarion, Proteome Systems and MindsetRx. He serves as Chairman of the Board of Sensorion (www.sensorion-pharma.com) and Board Member at Genomic Vision (www.genomicvision.com) and EyeGate Pharma (www.eyegatepharma.com). He is Advisor to the Mulhouse based company Rhenovia Pharma (www.rhenovia.com). Since 2002 he has served as Foreign Trade Advisor to the French government (www.ccefboston.org).(top)

Johannes Fruehauf (MD PhD) (Founder and Chief Scientific Officer)
Dr. Fruehauf is a serial entrepreneur and scientist with a track record in building successful biotechnology companies. He is the owner of Cambridge BioLabs, an early-stage contract research organization in Kendall Square. He is also the Founder & President of LabCentral, a large non-profit shared laboratory for startup life science companies. Before starting ViThera, he was a co-founder of Cequent Pharmaceuticals (sold to Marina Biotech, Nasdaq MRNA) and served as Head of R&D. He serves as a Board Director or advisor to a number of biotechnology companies. He completed his post-doc with Dr. Chiang Li at the Beth Israel Deaconess Medical Center and invented the bacterial RNAi technology transkingdom RNA interference, the only RNAi therapeutic targeting the gastrointestinal tract. Dr. Fruehauf is the author of over 20 peer reviewed publications and is a named inventor on 14 patents related to RNA interference and bacterial therapeutics.(top)

Lisa Velardo (CPA) (Chief Financial Officer)
Ms. Velardo joins the ViThera team with years of financial and operational experience in a broad range of venture-funded companies. She contributes extensive financial management expertise in areas of financial operations and reporting, budgeting and forecasting, technical accounting and taxation. Prior to joining ViThera, Ms.Velardo held various senior financial management positions in life sciences, technology and service organizations, including, Boston Biomedical, Gnu Bio, Cequent Pharmaceuticals, Boston Heart Lab, Castlewood Sugical and Cambridge BioLabs. In addition to her finance operational roles, Lisa served as Director of Finance at the private equity firm Watermill Ventures. While at Watermill, Lisa worked on the diligence, acquisition, repositioning and sale of middle market companies and provided financial advisory services to portfolio companies. Ms. Velardo is a Certified Public Accountant (CPA) and holds a BS in Business Administration from Merrimack College. (top)

F. Stephen Laroux (PhD) (Consultant, Inflammatory Diseases)
Dr. Laroux is Director, Inflammatory Diseases and Immunology at ViThera. Most recently, Dr. Laroux was Director of Immunology and Inflammatory Diseases at Cequent Pharmaceuticals, where he directed the preclinical discovery efforts and large-pharma collaborations based on the tkRNAi platform.Dr. Laroux completed a post-doctoral fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School where he conducted research focused on innate immune responses to bacteria as well as the role of the immune system in chronic disease. Prior to his tenure at BIDMC, Dr. Laroux conducted research into the immunology of diseases such as IBD, rheumatoid arthritis, ischemia-reperfusion and myocardial infarction, co-authoring over 40 publications in peer reviewed journals. Dr. Laroux received his Master's degree in Human Physiology in 2000 and his PhD (Chancellor's Award) in Molecular and Cellular Physiology in 2003 both from Louisiana State University.(top)

Laura Holberger (PhD) (Scientist)
Laura Holberger is responsible for the engineering of novel therapeutic strains and platform development for ViThera's EnLact(TM) technology. Dr. Holberger has extensive experience in the molecular genetics of gram-positive bacteria. She received her undergraduate degree in Biochemistry and International studies from Worcester Polytechnic Institute in Worcester, MA. Dr. Holberger has a strong industry background beginning with her employment at Capsule Technologies and later at Idexx Laboratories. She completed her doctoral studies at University of California Santa Barbara where she performed groundbreaking research concerning cytotoxic RNAses produced by gram-positive bacteria in response to starvation. While working toward her PhD, Ms. Holberger also earned a certificate degree in Technology Management Practice.  (top)